Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
20/05/2024 | 21:32 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:VRTX | Vertex Pharmaceuticals Inc |
20/05/2024 | 14:36 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:VRTX | Vertex Pharmaceuticals Inc |
20/05/2024 | 14:25 | Edgar (US Regulatory) | Form SC TO-T/A - Tender offer statement by Third Party: [Amend] | NASDAQ:VRTX | Vertex Pharmaceuticals Inc |
17/05/2024 | 22:27 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:VRTX | Vertex Pharmaceuticals Inc |
17/05/2024 | 22:16 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:VRTX | Vertex Pharmaceuticals Inc |
15/05/2024 | 16:30 | Business Wire | Jennifer Schneider Elected to Vertex Board of Directors | NASDAQ:VRTX | Vertex Pharmaceuticals Inc |
07/05/2024 | 22:14 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:VRTX | Vertex Pharmaceuticals Inc |
07/05/2024 | 13:46 | IH Market News | Disney Slashes Streaming Losses, UBS shoots up 9% as profit triples expectations, and More in Earnings | NASDAQ:VRTX | Vertex Pharmaceuticals Inc |
06/05/2024 | 22:01 | Business Wire | Vertex Reports First Quarter 2024 Financial Results | NASDAQ:VRTX | Vertex Pharmaceuticals Inc |
06/05/2024 | 14:09 | IH Market News | Index Futures Point to Strong Monday Opening, Building on Last Week’s Gains; Oil Prices Rise | NASDAQ:VRTX | Vertex Pharmaceuticals Inc |
26/04/2024 | 17:43 | Business Wire | Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older | NASDAQ:VRTX | Vertex Pharmaceuticals Inc |
23/04/2024 | 06:45 | PR Newswire (Canada) | VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES | NASDAQ:VRTX | Vertex Pharmaceuticals Inc |
18/04/2024 | 14:00 | Business Wire | Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain | NASDAQ:VRTX | Vertex Pharmaceuticals Inc |
11/04/2024 | 13:24 | IH Market News | Costco Increases Dividend by 14%, Meta Introduces ‘Artemis’ AI Chip, and More News | NASDAQ:VRTX | Vertex Pharmaceuticals Inc |
10/04/2024 | 22:01 | Business Wire | Vertex Enters Into Agreement to Acquire Alpine Immune Sciences | NASDAQ:VRTX | Vertex Pharmaceuticals Inc |
09/04/2024 | 22:05 | Business Wire | Vertex to Announce First Quarter 2024 Financial Results on May 6 | NASDAQ:VRTX | Vertex Pharmaceuticals Inc |
01/04/2024 | 17:00 | PR Newswire (Canada) | Vertex Announces New Drug Submission for Exagamglogene Autotemcel (exa-cel) Has Been Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia | NASDAQ:VRTX | Vertex Pharmaceuticals Inc |
01/04/2024 | 17:00 | PR Newswire (Canada) | Vertex annonce que la présentation de drogue nouvelle d'Exagamglogène Autotemcel (exa-cel) a été acceptée pour évaluation prioritaire par Santé Canada pour le traitement de l'anémie falciforme et de la bêta-thalassémie dépendante des transfusion | NASDAQ:VRTX | Vertex Pharmaceuticals Inc |
01/04/2024 | 14:00 | Business Wire | Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease | NASDAQ:VRTX | Vertex Pharmaceuticals Inc |
21/03/2024 | 13:00 | Business Wire | Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) | NASDAQ:VRTX | Vertex Pharmaceuticals Inc |
23/02/2024 | 13:10 | Business Wire | Vertex Receives CHMP Positive Opinion for KALYDECO® for the Treatment of Infants With Cystic Fibrosis Ages 1 Month and Older | NASDAQ:VRTX | Vertex Pharmaceuticals Inc |
20/02/2024 | 22:05 | Business Wire | Vertex to Participate in Upcoming Investor Conferences | NASDAQ:VRTX | Vertex Pharmaceuticals Inc |
13/02/2024 | 07:59 | Business Wire | European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia | NASDAQ:VRTX | Vertex Pharmaceuticals Inc |
10/02/2024 | 00:19 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:VRTX | Vertex Pharmaceuticals Inc |
06/02/2024 | 12:14 | IH Market News | Boeing Faces Strike Threat, Palantir Up 18% After Recording its First Profitable Year, and More | NASDAQ:VRTX | Vertex Pharmaceuticals Inc |
05/02/2024 | 22:06 | Business Wire | Vertex Reports Fourth Quarter and Full Year 2023 Financial Results | NASDAQ:VRTX | Vertex Pharmaceuticals Inc |
05/02/2024 | 22:01 | Business Wire | Vertex Announces Positive Results From Pivotal Trials of Vanzacaftor/Tezacaftor/Deutivacaftor, Next-In-Class Triple Combination Treatment for Cystic Fibrosis | NASDAQ:VRTX | Vertex Pharmaceuticals Inc |
30/01/2024 | 12:28 | Business Wire | Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain | NASDAQ:VRTX | Vertex Pharmaceuticals Inc |
25/01/2024 | 19:48 | Edgar (US Regulatory) | Form SC 13G - Statement of acquisition of beneficial ownership by individuals | NASDAQ:VRTX | Vertex Pharmaceuticals Inc |
17/01/2024 | 14:00 | Business Wire | Vertex to Announce Fourth Quarter and Full Year 2023 Financial Results on February 5 | NASDAQ:VRTX | Vertex Pharmaceuticals Inc |